Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-response study of BOTOX in idiopathic overactive bladder with urinary urge incontinence
2005-001936-59Phase 2Completed
- Sponsor
- Allergan
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in overactive bladder (OAB) (6 arms), sponsored by Allergan. Started Jun 2005; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-001936-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001936-59.